Kyverna Therapeutics announced positive one-year topline data for its Miv-Cel trial in Stiff Person Syndrome (SPS) and longer-term follow-up data for Generalized Myasthenia Gravis (gMG), showing sustained clinical benefit and a well-tolerated safety profile. This data reinforces the potential for Miv-Cel as a single-dose therapy for autoimmune diseases, with a rolling BLA submission for SPS on track for Q4 2026.
Kyverna Therapeutics (KYTX) released positive one-year data for its Miv-Cel trial in Stiff Person Syndrome (SPS) and longer-term follow-up data for Generalized Myasthenia Gravis (gMG). The data indicates sustained clinical benefit, reversal of disability, and a favorable safety profile, positioning Miv-Cel as a potential first-in-class approved therapy for SPS and the first CAR T-cell therapy for autoimmune disease. This is a significant positive development for KYTX, as it de-risks their lead candidate and strengthens their market position. Short-term, this could lead to increased investor confidence and stock appreciation. Long-term, successful BLA submission and market approval could unlock substantial revenue streams. The key opportunity for traders is the potential for continued upward momentum as the BLA submission progresses and Phase 3 enrollment for gMG continues.